Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Depot risperidone for schizophrenia.

P Hosalli1, J M Davis

  • 1Academic Unit of Psychiatry and Behavioural Sciences, University of Leeds, 15 Hyde Terrace, Leeds, UK, LS2 9LT.

The Cochrane Database of Systematic Reviews
|October 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of ethanol administration and withdrawal on serotonin receptor subtypes and receptor-mediated phosphoinositide hydrolysis in rat brain.

Alcoholism, clinical and experimental research·1992
Same author

Effects of brief, heavy exertion on circulating lymphocyte subpopulations and proliferative response.

Medicine and science in sports and exercise·1992
Same author

Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients.

Schizophrenia research·1992
Same author

Monoamine oxidase and cortisol response in depression and schizophrenia.

Psychiatry research·1992
Same author

Platelet monoamine oxidase in schizophrenia: a meta-analysis.

Schizophrenia research·1992
Same author

Effect of electroconvulsive shock on 5-HT2 and alpha 1-adrenoceptors and phosphoinositide signalling system in rat brain.

European journal of pharmacology·1992
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
See all related articles

Depot risperidone, a long-acting injectable antipsychotic, shows limited reliable data for schizophrenia treatment. While it may improve compliance in some patients, adverse effects and movement disorders require further investigation.

Area of Science:

  • Psychiatry and Clinical Pharmacology
  • Neuroscience and Mental Health Research

Background:

  • Risperidone represents a novel advancement as the first long-acting injectable antipsychotic in the new generation of psychotropic medications.
  • The development of long-acting injectable formulations aims to improve medication adherence and treatment outcomes for chronic psychiatric conditions.

Purpose of the Study:

  • To systematically evaluate the clinical efficacy and safety of depot risperidone in patients diagnosed with schizophrenia and schizophrenia-like psychoses.
  • To synthesize evidence from randomized clinical trials to inform clinical practice regarding the use of long-acting injectable risperidone.

Main Methods:

  • Conducted a comprehensive literature search of the Cochrane Schizophrenia Group's Register and other relevant databases.
  • Included randomized clinical trials comparing depot risperidone against placebo or other active treatments for schizophrenia spectrum disorders.

Related Experiment Videos

  • Employed rigorous data extraction and statistical analysis, including relative risks and weighted mean differences, on an intention-to-treat basis.

    • Main Results:

    • One study comparing depot risperidone to placebo indicated potential reduction in agitation and overall 'psychosis', with higher attrition in the placebo group.
    • However, data quality was compromised by high dropout rates (56%) in the placebo-controlled trial, limiting interpretation of global and mental state outcomes.
    • A separate study comparing depot risperidone to oral risperidone in stable patients showed no significant differences in global or mental state outcomes, though compliance was good; adverse effects were poorly reported in both groups.

    Conclusions:

    • Currently, there is insufficient reliable data to definitively establish the benefits of depot risperidone for schizophrenia.
    • While depot risperidone might offer an alternative to oral dosing for stable patients, its adverse effect profile, including a potential association with movement disorders at higher doses, requires careful consideration and further research.
    • High-quality, well-reported randomized controlled trials grounded in clinical practice are essential to fully ascertain the therapeutic value of depot risperidone.